nodes	percent_of_prediction	percent_of_DWPC	metapath
Imiquimod—skin cancer—psoriasis	0.64	1	CtDrD
Imiquimod—CYP1A2—Clobetasol propionate—psoriasis	0.0494	0.296	CbGbCtD
Imiquimod—CYP1A2—Methoxsalen—psoriasis	0.026	0.156	CbGbCtD
Imiquimod—CYP3A4—Calcitriol—psoriasis	0.0175	0.105	CbGbCtD
Imiquimod—CYP3A4—Methoxsalen—psoriasis	0.0136	0.0816	CbGbCtD
Imiquimod—CYP3A4—Cholecalciferol—psoriasis	0.00901	0.054	CbGbCtD
Imiquimod—CYP3A4—Mycophenolate mofetil—psoriasis	0.00781	0.0468	CbGbCtD
Imiquimod—CYP3A4—Triamcinolone—psoriasis	0.00781	0.0468	CbGbCtD
Imiquimod—CYP3A4—Betamethasone—psoriasis	0.0067	0.0402	CbGbCtD
Imiquimod—CYP3A4—Prednisolone—psoriasis	0.00661	0.0397	CbGbCtD
Imiquimod—CYP3A4—Hydrocortisone—psoriasis	0.00627	0.0376	CbGbCtD
Imiquimod—CYP3A4—Prednisone—psoriasis	0.00624	0.0374	CbGbCtD
Imiquimod—CYP3A4—Cyclosporine—psoriasis	0.00592	0.0355	CbGbCtD
Imiquimod—CYP3A4—Dexamethasone—psoriasis	0.0039	0.0234	CbGbCtD
Imiquimod—TLR8—Toll-like Receptor Signaling Pathway—IL12B—psoriasis	0.000879	0.0228	CbGpPWpGaD
Imiquimod—TLR8—Regulation of toll-like receptor signaling pathway—TNFAIP3—psoriasis	0.000797	0.0207	CbGpPWpGaD
Imiquimod—TLR8—Regulation of toll-like receptor signaling pathway—IL12B—psoriasis	0.000686	0.0178	CbGpPWpGaD
Imiquimod—TLR7—Toll-like Receptor Signaling Pathway—IL12B—psoriasis	0.000666	0.0173	CbGpPWpGaD
Imiquimod—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.000637	0.0165	CbGpPWpGaD
Imiquimod—TLR7—Regulation of toll-like receptor signaling pathway—TNFAIP3—psoriasis	0.000604	0.0157	CbGpPWpGaD
Imiquimod—TLR8—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NFKBIA—psoriasis	0.000565	0.0146	CbGpPWpGaD
Imiquimod—TLR8—Regulation of toll-like receptor signaling pathway—SOCS1—psoriasis	0.000559	0.0145	CbGpPWpGaD
Imiquimod—TLR8—MyD88 dependent cascade initiated on endosome—NFKBIA—psoriasis	0.000555	0.0144	CbGpPWpGaD
Imiquimod—TLR8—Toll-Like Receptors Cascades—SOCS1—psoriasis	0.000553	0.0143	CbGpPWpGaD
Imiquimod—TLR8—Toll Like Receptor 9 (TLR9) Cascade—NFKBIA—psoriasis	0.000535	0.0139	CbGpPWpGaD
Imiquimod—TLR7—Regulation of toll-like receptor signaling pathway—IL12B—psoriasis	0.00052	0.0135	CbGpPWpGaD
Imiquimod—TLR8—Immune System—KIR2DS1—psoriasis	0.000512	0.0133	CbGpPWpGaD
Imiquimod—TLR8—Toll-like Receptor Signaling Pathway—NFKBIA—psoriasis	0.000493	0.0128	CbGpPWpGaD
Imiquimod—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000492	0.0127	CbGpPWpGaD
Imiquimod—TLR8—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—TYK2—psoriasis	0.000463	0.012	CbGpPWpGaD
Imiquimod—TLR8—MyD88 dependent cascade initiated on endosome—TYK2—psoriasis	0.000454	0.0118	CbGpPWpGaD
Imiquimod—TLR8—Toll Like Receptor 9 (TLR9) Cascade—TYK2—psoriasis	0.000438	0.0114	CbGpPWpGaD
Imiquimod—TLR7—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NFKBIA—psoriasis	0.000428	0.0111	CbGpPWpGaD
Imiquimod—TLR7—Regulation of toll-like receptor signaling pathway—SOCS1—psoriasis	0.000424	0.011	CbGpPWpGaD
Imiquimod—TLR7—MyD88 dependent cascade initiated on endosome—NFKBIA—psoriasis	0.00042	0.0109	CbGpPWpGaD
Imiquimod—TLR7—Toll-Like Receptors Cascades—SOCS1—psoriasis	0.000419	0.0109	CbGpPWpGaD
Imiquimod—TLR7—Toll Like Receptor 9 (TLR9) Cascade—NFKBIA—psoriasis	0.000406	0.0105	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—DDX58—psoriasis	0.000396	0.0103	CbGpPWpGaD
Imiquimod—TLR7—Immune System—KIR2DS1—psoriasis	0.000388	0.0101	CbGpPWpGaD
Imiquimod—TLR8—Regulation of toll-like receptor signaling pathway—NFKBIA—psoriasis	0.000385	0.00997	CbGpPWpGaD
Imiquimod—TLR8—Toll-Like Receptors Cascades—NFKBIA—psoriasis	0.00038	0.00986	CbGpPWpGaD
Imiquimod—TLR8—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—JUN—psoriasis	0.000374	0.00971	CbGpPWpGaD
Imiquimod—TLR7—Toll-like Receptor Signaling Pathway—NFKBIA—psoriasis	0.000373	0.00968	CbGpPWpGaD
Imiquimod—TLR8—MyD88 dependent cascade initiated on endosome—JUN—psoriasis	0.000368	0.00953	CbGpPWpGaD
Imiquimod—TLR8—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NFKB1—psoriasis	0.00036	0.00934	CbGpPWpGaD
Imiquimod—TLR8—Toll Like Receptor 9 (TLR9) Cascade—JUN—psoriasis	0.000355	0.0092	CbGpPWpGaD
Imiquimod—TLR8—MyD88 dependent cascade initiated on endosome—NFKB1—psoriasis	0.000354	0.00917	CbGpPWpGaD
Imiquimod—TLR8—Toll-like Receptor Signaling Pathway—CXCL8—psoriasis	0.000351	0.00911	CbGpPWpGaD
Imiquimod—TLR7—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—TYK2—psoriasis	0.000351	0.00909	CbGpPWpGaD
Imiquimod—TLR7—MyD88 dependent cascade initiated on endosome—TYK2—psoriasis	0.000344	0.00892	CbGpPWpGaD
Imiquimod—TLR8—Toll Like Receptor 9 (TLR9) Cascade—NFKB1—psoriasis	0.000342	0.00885	CbGpPWpGaD
Imiquimod—TLR7—Toll Like Receptor 9 (TLR9) Cascade—TYK2—psoriasis	0.000332	0.00861	CbGpPWpGaD
Imiquimod—TLR8—Toll-like Receptor Signaling Pathway—JUN—psoriasis	0.000327	0.00847	CbGpPWpGaD
Imiquimod—TLR8—Toll-like Receptor Signaling Pathway—NFKB1—psoriasis	0.000314	0.00815	CbGpPWpGaD
Imiquimod—TLR8—Toll-Like Receptors Cascades—TYK2—psoriasis	0.000312	0.00808	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—DDX58—psoriasis	0.0003	0.00778	CbGpPWpGaD
Imiquimod—TLR7—Regulation of toll-like receptor signaling pathway—NFKBIA—psoriasis	0.000292	0.00756	CbGpPWpGaD
Imiquimod—TLR7—Toll-Like Receptors Cascades—NFKBIA—psoriasis	0.000288	0.00747	CbGpPWpGaD
Imiquimod—TLR7—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—JUN—psoriasis	0.000284	0.00736	CbGpPWpGaD
Imiquimod—TLR7—MyD88 dependent cascade initiated on endosome—JUN—psoriasis	0.000279	0.00722	CbGpPWpGaD
Imiquimod—TLR8—Regulation of toll-like receptor signaling pathway—CXCL8—psoriasis	0.000274	0.00711	CbGpPWpGaD
Imiquimod—TLR7—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NFKB1—psoriasis	0.000273	0.00708	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—IFIH1—psoriasis	0.000273	0.00707	CbGpPWpGaD
Imiquimod—TLR7—Toll Like Receptor 9 (TLR9) Cascade—JUN—psoriasis	0.000269	0.00697	CbGpPWpGaD
Imiquimod—TLR7—MyD88 dependent cascade initiated on endosome—NFKB1—psoriasis	0.000268	0.00695	CbGpPWpGaD
Imiquimod—TLR7—Toll-like Receptor Signaling Pathway—CXCL8—psoriasis	0.000266	0.0069	CbGpPWpGaD
Imiquimod—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000264	0.00686	CbGpPWpGaD
Imiquimod—TLR8—Immune System—ERAP1—psoriasis	0.000262	0.00679	CbGpPWpGaD
Imiquimod—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000261	0.00677	CbGpPWpGaD
Imiquimod—TLR7—Toll Like Receptor 9 (TLR9) Cascade—NFKB1—psoriasis	0.000259	0.00671	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—HLA-C—psoriasis	0.000258	0.0067	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—TNFAIP3—psoriasis	0.000255	0.00662	CbGpPWpGaD
Imiquimod—TLR8—Regulation of toll-like receptor signaling pathway—JUN—psoriasis	0.000255	0.00661	CbGpPWpGaD
Imiquimod—TLR8—Toll-Like Receptors Cascades—JUN—psoriasis	0.000252	0.00654	CbGpPWpGaD
Imiquimod—TLR7—Toll-like Receptor Signaling Pathway—JUN—psoriasis	0.000248	0.00642	CbGpPWpGaD
Imiquimod—TLR8—Regulation of toll-like receptor signaling pathway—NFKB1—psoriasis	0.000246	0.00636	CbGpPWpGaD
Imiquimod—TLR8—Toll-like Receptor Signaling Pathway—TNF—psoriasis	0.000245	0.00634	CbGpPWpGaD
Imiquimod—TLR8—Toll-Like Receptors Cascades—NFKB1—psoriasis	0.000243	0.00629	CbGpPWpGaD
Imiquimod—TLR7—Toll-like Receptor Signaling Pathway—NFKB1—psoriasis	0.000238	0.00618	CbGpPWpGaD
Imiquimod—TLR7—Toll-Like Receptors Cascades—TYK2—psoriasis	0.000236	0.00612	CbGpPWpGaD
Imiquimod—TLR8—Immune System—DDX58—psoriasis	0.000231	0.00598	CbGpPWpGaD
Imiquimod—TLR8—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—IL6—psoriasis	0.000226	0.00587	CbGpPWpGaD
Imiquimod—TLR8—MyD88 dependent cascade initiated on endosome—IL6—psoriasis	0.000222	0.00576	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—HLA-E—psoriasis	0.000214	0.00556	CbGpPWpGaD
Imiquimod—TLR8—Toll Like Receptor 9 (TLR9) Cascade—IL6—psoriasis	0.000214	0.00556	CbGpPWpGaD
Imiquimod—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000214	0.00556	CbGpPWpGaD
Imiquimod—TLR7—Regulation of toll-like receptor signaling pathway—CXCL8—psoriasis	0.000208	0.00539	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—IFIH1—psoriasis	0.000207	0.00536	CbGpPWpGaD
Imiquimod—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000204	0.00529	CbGpPWpGaD
Imiquimod—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000201	0.00522	CbGpPWpGaD
Imiquimod—TLR7—Immune System—ERAP1—psoriasis	0.000199	0.00515	CbGpPWpGaD
Imiquimod—TLR8—Toll-like Receptor Signaling Pathway—IL6—psoriasis	0.000197	0.00512	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—HLA-C—psoriasis	0.000196	0.00508	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—TNFAIP3—psoriasis	0.000193	0.00502	CbGpPWpGaD
Imiquimod—TLR7—Regulation of toll-like receptor signaling pathway—JUN—psoriasis	0.000193	0.00501	CbGpPWpGaD
Imiquimod—TLR7—Toll-Like Receptors Cascades—JUN—psoriasis	0.000191	0.00495	CbGpPWpGaD
Imiquimod—TLR8—Regulation of toll-like receptor signaling pathway—TNF—psoriasis	0.000191	0.00495	CbGpPWpGaD
Imiquimod—TLR7—Regulation of toll-like receptor signaling pathway—NFKB1—psoriasis	0.000186	0.00482	CbGpPWpGaD
Imiquimod—TLR7—Toll-like Receptor Signaling Pathway—TNF—psoriasis	0.000185	0.00481	CbGpPWpGaD
Imiquimod—TLR7—Toll-Like Receptors Cascades—NFKB1—psoriasis	0.000184	0.00477	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—SOCS1—psoriasis	0.000179	0.00464	CbGpPWpGaD
Imiquimod—TLR7—Immune System—DDX58—psoriasis	0.000175	0.00453	CbGpPWpGaD
Imiquimod—TLR8—Immune System—ITGAL—psoriasis	0.000175	0.00453	CbGpPWpGaD
Imiquimod—TLR7—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—IL6—psoriasis	0.000171	0.00445	CbGpPWpGaD
Imiquimod—TLR7—MyD88 dependent cascade initiated on endosome—IL6—psoriasis	0.000168	0.00436	CbGpPWpGaD
Imiquimod—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000165	0.00429	CbGpPWpGaD
Imiquimod—TLR8—Immune System—REL—psoriasis	0.000164	0.00424	CbGpPWpGaD
Imiquimod—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000163	0.00423	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—HLA-E—psoriasis	0.000163	0.00421	CbGpPWpGaD
Imiquimod—TLR7—Toll Like Receptor 9 (TLR9) Cascade—IL6—psoriasis	0.000162	0.00421	CbGpPWpGaD
Imiquimod—TLR8—Immune System—IFIH1—psoriasis	0.000159	0.00412	CbGpPWpGaD
Imiquimod—TLR8—Regulation of toll-like receptor signaling pathway—IL6—psoriasis	0.000154	0.00399	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—HLA-B—psoriasis	0.000153	0.00396	CbGpPWpGaD
Imiquimod—TLR8—Toll-Like Receptors Cascades—IL6—psoriasis	0.000152	0.00395	CbGpPWpGaD
Imiquimod—TLR8—Immune System—HLA-C—psoriasis	0.000151	0.0039	CbGpPWpGaD
Imiquimod—TLR7—Toll-like Receptor Signaling Pathway—IL6—psoriasis	0.00015	0.00388	CbGpPWpGaD
Imiquimod—TLR8—Immune System—TNFAIP3—psoriasis	0.000149	0.00385	CbGpPWpGaD
Imiquimod—TLR7—Regulation of toll-like receptor signaling pathway—TNF—psoriasis	0.000145	0.00375	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—SOCS1—psoriasis	0.000136	0.00352	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—CRP—psoriasis	0.000135	0.0035	CbGpPWpGaD
Imiquimod—TLR7—Immune System—ITGAL—psoriasis	0.000133	0.00344	CbGpPWpGaD
Imiquimod—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.00013	0.00336	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000127	0.00329	CbGpPWpGaD
Imiquimod—TLR8—Immune System—HLA-E—psoriasis	0.000125	0.00324	CbGpPWpGaD
Imiquimod—TLR7—Immune System—REL—psoriasis	0.000124	0.00321	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—NFKBIA—psoriasis	0.000123	0.00319	CbGpPWpGaD
Imiquimod—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000121	0.00315	CbGpPWpGaD
Imiquimod—TLR7—Immune System—IFIH1—psoriasis	0.00012	0.00312	CbGpPWpGaD
Imiquimod—TLR7—Regulation of toll-like receptor signaling pathway—IL6—psoriasis	0.000117	0.00303	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—HLA-B—psoriasis	0.000116	0.003	CbGpPWpGaD
Imiquimod—TLR7—Toll-Like Receptors Cascades—IL6—psoriasis	0.000115	0.00299	CbGpPWpGaD
Imiquimod—TLR7—Immune System—HLA-C—psoriasis	0.000114	0.00296	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—CYP2S1—psoriasis	0.000114	0.00295	CbGpPWpGaD
Imiquimod—TLR7—Immune System—TNFAIP3—psoriasis	0.000113	0.00292	CbGpPWpGaD
Imiquimod—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	0.000112	0.00291	CbGpPWpGaD
Imiquimod—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	0.000112	0.00291	CbGpPWpGaD
Imiquimod—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	0.00011	0.00286	CbGpPWpGaD
Imiquimod—TLR8—Immune System—SOCS1—psoriasis	0.000104	0.0027	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—CRP—psoriasis	0.000102	0.00265	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—TYK2—psoriasis	0.000101	0.00262	CbGpPWpGaD
Imiquimod—CYP1A2—Tryptophan metabolism—CAT—psoriasis	9.82e-05	0.00255	CbGpPWpGaD
Imiquimod—TLR7—Immune System—HLA-E—psoriasis	9.47e-05	0.00245	CbGpPWpGaD
Imiquimod—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	9.37e-05	0.00243	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—NFKBIA—psoriasis	9.34e-05	0.00242	CbGpPWpGaD
Imiquimod—TLR8—Immune System—CD8A—psoriasis	9.25e-05	0.0024	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—CD4—psoriasis	9.13e-05	0.00237	CbGpPWpGaD
Imiquimod—TLR8—Immune System—HLA-B—psoriasis	8.9e-05	0.00231	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—CYP2S1—psoriasis	8.79e-05	0.00228	CbGpPWpGaD
Imiquimod—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	8.67e-05	0.00225	CbGpPWpGaD
Imiquimod—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.47e-05	0.0022	CbGpPWpGaD
Imiquimod—TLR8—Immune System—HLA-A—psoriasis	8.25e-05	0.00214	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—JUN—psoriasis	8.17e-05	0.00212	CbGpPWpGaD
Imiquimod—TLR7—Immune System—SOCS1—psoriasis	7.91e-05	0.00205	CbGpPWpGaD
Imiquimod—TLR8—Immune System—CRP—psoriasis	7.87e-05	0.00204	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—NFKB1—psoriasis	7.86e-05	0.00204	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—TYK2—psoriasis	7.65e-05	0.00198	CbGpPWpGaD
Imiquimod—CYP3A4—Tryptophan metabolism—CAT—psoriasis	7.58e-05	0.00197	CbGpPWpGaD
Imiquimod—TLR8—Immune System—HLA-DRB1—psoriasis	7.54e-05	0.00195	CbGpPWpGaD
Imiquimod—TLR8—Immune System—ICAM1—psoriasis	7.23e-05	0.00187	CbGpPWpGaD
Imiquimod—TLR8—Immune System—NFKBIA—psoriasis	7.18e-05	0.00186	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CD8A—psoriasis	7.01e-05	0.00182	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—CD4—psoriasis	6.92e-05	0.00179	CbGpPWpGaD
Imiquimod—TLR7—Immune System—HLA-B—psoriasis	6.75e-05	0.00175	CbGpPWpGaD
Imiquimod—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	6.57e-05	0.0017	CbGpPWpGaD
Imiquimod—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.54e-05	0.00169	CbGpPWpGaD
Imiquimod—TLR7—Immune System—HLA-A—psoriasis	6.25e-05	0.00162	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—JUN—psoriasis	6.19e-05	0.0016	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CRP—psoriasis	5.96e-05	0.00155	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—NFKB1—psoriasis	5.96e-05	0.00154	CbGpPWpGaD
Imiquimod—TLR8—Immune System—TYK2—psoriasis	5.88e-05	0.00152	CbGpPWpGaD
Imiquimod—TLR7—Immune System—HLA-DRB1—psoriasis	5.71e-05	0.00148	CbGpPWpGaD
Imiquimod—TLR8—Immune System—IFNG—psoriasis	5.5e-05	0.00143	CbGpPWpGaD
Imiquimod—TLR7—Immune System—ICAM1—psoriasis	5.48e-05	0.00142	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	5.46e-05	0.00141	CbGpPWpGaD
Imiquimod—TLR7—Immune System—NFKBIA—psoriasis	5.44e-05	0.00141	CbGpPWpGaD
Imiquimod—TLR8—Immune System—CD4—psoriasis	5.31e-05	0.00138	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—IL6—psoriasis	4.94e-05	0.00128	CbGpPWpGaD
Imiquimod—TLR8—Immune System—JUN—psoriasis	4.76e-05	0.00123	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	4.72e-05	0.00122	CbGpPWpGaD
Imiquimod—TLR8—Immune System—NFKB1—psoriasis	4.58e-05	0.00119	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	4.54e-05	0.00118	CbGpPWpGaD
Imiquimod—TLR7—Immune System—TYK2—psoriasis	4.45e-05	0.00115	CbGpPWpGaD
Imiquimod—TLR7—Immune System—IFNG—psoriasis	4.17e-05	0.00108	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	4.12e-05	0.00107	CbGpPWpGaD
Imiquimod—TLR8—Immune System—STAT3—psoriasis	4.12e-05	0.00107	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CD4—psoriasis	4.03e-05	0.00104	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—IL6—psoriasis	3.74e-05	0.00097	CbGpPWpGaD
Imiquimod—TLR7—Immune System—JUN—psoriasis	3.61e-05	0.000935	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	3.53e-05	0.000915	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	3.53e-05	0.000915	CbGpPWpGaD
Imiquimod—TLR7—Immune System—NFKB1—psoriasis	3.47e-05	0.0009	CbGpPWpGaD
Imiquimod—TLR7—Immune System—STAT3—psoriasis	3.12e-05	0.000808	CbGpPWpGaD
Imiquimod—TLR8—Immune System—IL6—psoriasis	2.87e-05	0.000745	CbGpPWpGaD
Imiquimod—Convulsion—Betamethasone—psoriasis	2.77e-05	0.000178	CcSEcCtD
Imiquimod—Convulsion—Dexamethasone—psoriasis	2.77e-05	0.000178	CcSEcCtD
Imiquimod—Feeling abnormal—Mycophenolate mofetil—psoriasis	2.76e-05	0.000178	CcSEcCtD
Imiquimod—Insomnia—Hydrocortisone—psoriasis	2.76e-05	0.000178	CcSEcCtD
Imiquimod—Hypertension—Dexamethasone—psoriasis	2.76e-05	0.000178	CcSEcCtD
Imiquimod—Hypertension—Betamethasone—psoriasis	2.76e-05	0.000178	CcSEcCtD
Imiquimod—Paraesthesia—Hydrocortisone—psoriasis	2.74e-05	0.000176	CcSEcCtD
Imiquimod—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	2.74e-05	0.000176	CcSEcCtD
Imiquimod—Urticaria—Cyclosporine—psoriasis	2.73e-05	0.000176	CcSEcCtD
Imiquimod—Myalgia—Dexamethasone—psoriasis	2.72e-05	0.000175	CcSEcCtD
Imiquimod—Myalgia—Betamethasone—psoriasis	2.72e-05	0.000175	CcSEcCtD
Imiquimod—Body temperature increased—Cyclosporine—psoriasis	2.71e-05	0.000175	CcSEcCtD
Imiquimod—Abdominal pain—Cyclosporine—psoriasis	2.71e-05	0.000175	CcSEcCtD
Imiquimod—Anxiety—Dexamethasone—psoriasis	2.71e-05	0.000175	CcSEcCtD
Imiquimod—Anxiety—Betamethasone—psoriasis	2.71e-05	0.000175	CcSEcCtD
Imiquimod—Vomiting—Mycophenolic acid—psoriasis	2.7e-05	0.000174	CcSEcCtD
Imiquimod—Discomfort—Betamethasone—psoriasis	2.68e-05	0.000173	CcSEcCtD
Imiquimod—Discomfort—Dexamethasone—psoriasis	2.68e-05	0.000173	CcSEcCtD
Imiquimod—Dyspepsia—Hydrocortisone—psoriasis	2.68e-05	0.000173	CcSEcCtD
Imiquimod—Haemoglobin—Methotrexate—psoriasis	2.68e-05	0.000173	CcSEcCtD
Imiquimod—Rash—Mycophenolic acid—psoriasis	2.67e-05	0.000172	CcSEcCtD
Imiquimod—Dermatitis—Mycophenolic acid—psoriasis	2.67e-05	0.000172	CcSEcCtD
Imiquimod—Pain—Prednisolone—psoriasis	2.67e-05	0.000172	CcSEcCtD
Imiquimod—Haemorrhage—Methotrexate—psoriasis	2.67e-05	0.000172	CcSEcCtD
Imiquimod—Urticaria—Mycophenolate mofetil—psoriasis	2.66e-05	0.000171	CcSEcCtD
Imiquimod—Headache—Mycophenolic acid—psoriasis	2.66e-05	0.000171	CcSEcCtD
Imiquimod—Decreased appetite—Hydrocortisone—psoriasis	2.65e-05	0.000171	CcSEcCtD
Imiquimod—Pharyngitis—Methotrexate—psoriasis	2.65e-05	0.000171	CcSEcCtD
Imiquimod—Abdominal pain—Mycophenolate mofetil—psoriasis	2.65e-05	0.000171	CcSEcCtD
Imiquimod—Body temperature increased—Mycophenolate mofetil—psoriasis	2.65e-05	0.000171	CcSEcCtD
Imiquimod—Urinary tract disorder—Methotrexate—psoriasis	2.64e-05	0.00017	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Hydrocortisone—psoriasis	2.63e-05	0.00017	CcSEcCtD
Imiquimod—Fatigue—Hydrocortisone—psoriasis	2.63e-05	0.000169	CcSEcCtD
Imiquimod—Urethral disorder—Methotrexate—psoriasis	2.62e-05	0.000169	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Triamcinolone—psoriasis	2.62e-05	0.000169	CcSEcCtD
Imiquimod—Pain—Hydrocortisone—psoriasis	2.61e-05	0.000168	CcSEcCtD
Imiquimod—Oedema—Betamethasone—psoriasis	2.61e-05	0.000168	CcSEcCtD
Imiquimod—Oedema—Dexamethasone—psoriasis	2.61e-05	0.000168	CcSEcCtD
Imiquimod—Insomnia—Triamcinolone—psoriasis	2.6e-05	0.000167	CcSEcCtD
Imiquimod—Infection—Dexamethasone—psoriasis	2.59e-05	0.000167	CcSEcCtD
Imiquimod—Infection—Betamethasone—psoriasis	2.59e-05	0.000167	CcSEcCtD
Imiquimod—Ill-defined disorder—Prednisone—psoriasis	2.58e-05	0.000166	CcSEcCtD
Imiquimod—Paraesthesia—Triamcinolone—psoriasis	2.58e-05	0.000166	CcSEcCtD
Imiquimod—Feeling abnormal—Prednisolone—psoriasis	2.57e-05	0.000166	CcSEcCtD
Imiquimod—Visual impairment—Methotrexate—psoriasis	2.57e-05	0.000166	CcSEcCtD
Imiquimod—Shock—Dexamethasone—psoriasis	2.56e-05	0.000165	CcSEcCtD
Imiquimod—Shock—Betamethasone—psoriasis	2.56e-05	0.000165	CcSEcCtD
Imiquimod—Dyspnoea—Triamcinolone—psoriasis	2.56e-05	0.000165	CcSEcCtD
Imiquimod—Nervous system disorder—Dexamethasone—psoriasis	2.55e-05	0.000165	CcSEcCtD
Imiquimod—Nervous system disorder—Betamethasone—psoriasis	2.55e-05	0.000165	CcSEcCtD
Imiquimod—Agitation—Prednisone—psoriasis	2.55e-05	0.000165	CcSEcCtD
Imiquimod—Tachycardia—Dexamethasone—psoriasis	2.54e-05	0.000164	CcSEcCtD
Imiquimod—Tachycardia—Betamethasone—psoriasis	2.54e-05	0.000164	CcSEcCtD
Imiquimod—Angioedema—Prednisone—psoriasis	2.54e-05	0.000164	CcSEcCtD
Imiquimod—Hypersensitivity—Cyclosporine—psoriasis	2.53e-05	0.000163	CcSEcCtD
Imiquimod—Dyspepsia—Triamcinolone—psoriasis	2.53e-05	0.000163	CcSEcCtD
Imiquimod—Erythema multiforme—Methotrexate—psoriasis	2.52e-05	0.000163	CcSEcCtD
Imiquimod—Nausea—Mycophenolic acid—psoriasis	2.52e-05	0.000162	CcSEcCtD
Imiquimod—Hyperhidrosis—Betamethasone—psoriasis	2.52e-05	0.000162	CcSEcCtD
Imiquimod—Hyperhidrosis—Dexamethasone—psoriasis	2.52e-05	0.000162	CcSEcCtD
Imiquimod—Feeling abnormal—Hydrocortisone—psoriasis	2.51e-05	0.000162	CcSEcCtD
Imiquimod—Malaise—Prednisone—psoriasis	2.51e-05	0.000162	CcSEcCtD
Imiquimod—Eye disorder—Methotrexate—psoriasis	2.49e-05	0.000161	CcSEcCtD
Imiquimod—Gastrointestinal pain—Hydrocortisone—psoriasis	2.49e-05	0.000161	CcSEcCtD
Imiquimod—Syncope—Prednisone—psoriasis	2.49e-05	0.000161	CcSEcCtD
Imiquimod—Tinnitus—Methotrexate—psoriasis	2.49e-05	0.00016	CcSEcCtD
Imiquimod—Anorexia—Betamethasone—psoriasis	2.48e-05	0.00016	CcSEcCtD
Imiquimod—Anorexia—Dexamethasone—psoriasis	2.48e-05	0.00016	CcSEcCtD
Imiquimod—Urticaria—Prednisolone—psoriasis	2.48e-05	0.00016	CcSEcCtD
Imiquimod—Fatigue—Triamcinolone—psoriasis	2.48e-05	0.00016	CcSEcCtD
Imiquimod—Hypersensitivity—Mycophenolate mofetil—psoriasis	2.47e-05	0.000159	CcSEcCtD
Imiquimod—Asthenia—Cyclosporine—psoriasis	2.46e-05	0.000159	CcSEcCtD
Imiquimod—Pain—Triamcinolone—psoriasis	2.46e-05	0.000158	CcSEcCtD
Imiquimod—Loss of consciousness—Prednisone—psoriasis	2.44e-05	0.000157	CcSEcCtD
Imiquimod—Pruritus—Cyclosporine—psoriasis	2.43e-05	0.000156	CcSEcCtD
Imiquimod—Urticaria—Hydrocortisone—psoriasis	2.42e-05	0.000156	CcSEcCtD
Imiquimod—Angiopathy—Methotrexate—psoriasis	2.42e-05	0.000156	CcSEcCtD
Imiquimod—Immune system disorder—Methotrexate—psoriasis	2.41e-05	0.000155	CcSEcCtD
Imiquimod—Body temperature increased—Hydrocortisone—psoriasis	2.41e-05	0.000155	CcSEcCtD
Imiquimod—Abdominal pain—Hydrocortisone—psoriasis	2.41e-05	0.000155	CcSEcCtD
Imiquimod—Convulsion—Prednisone—psoriasis	2.41e-05	0.000155	CcSEcCtD
Imiquimod—Mediastinal disorder—Methotrexate—psoriasis	2.41e-05	0.000155	CcSEcCtD
Imiquimod—Asthenia—Mycophenolate mofetil—psoriasis	2.4e-05	0.000155	CcSEcCtD
Imiquimod—Hypertension—Prednisone—psoriasis	2.4e-05	0.000155	CcSEcCtD
Imiquimod—Chills—Methotrexate—psoriasis	2.39e-05	0.000154	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Betamethasone—psoriasis	2.37e-05	0.000153	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Dexamethasone—psoriasis	2.37e-05	0.000153	CcSEcCtD
Imiquimod—Pruritus—Mycophenolate mofetil—psoriasis	2.37e-05	0.000153	CcSEcCtD
Imiquimod—Myalgia—Prednisone—psoriasis	2.37e-05	0.000153	CcSEcCtD
Imiquimod—Arthralgia—Prednisone—psoriasis	2.37e-05	0.000153	CcSEcCtD
Imiquimod—Feeling abnormal—Triamcinolone—psoriasis	2.37e-05	0.000152	CcSEcCtD
Imiquimod—Anxiety—Prednisone—psoriasis	2.36e-05	0.000152	CcSEcCtD
Imiquimod—Alopecia—Methotrexate—psoriasis	2.36e-05	0.000152	CcSEcCtD
Imiquimod—Insomnia—Dexamethasone—psoriasis	2.36e-05	0.000152	CcSEcCtD
Imiquimod—Insomnia—Betamethasone—psoriasis	2.36e-05	0.000152	CcSEcCtD
Imiquimod—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	2.35e-05	0.000151	CcSEcCtD
Imiquimod—Diarrhoea—Cyclosporine—psoriasis	2.35e-05	0.000151	CcSEcCtD
Imiquimod—Paraesthesia—Betamethasone—psoriasis	2.34e-05	0.000151	CcSEcCtD
Imiquimod—Paraesthesia—Dexamethasone—psoriasis	2.34e-05	0.000151	CcSEcCtD
Imiquimod—Discomfort—Prednisone—psoriasis	2.34e-05	0.000151	CcSEcCtD
Imiquimod—Mental disorder—Methotrexate—psoriasis	2.34e-05	0.000151	CcSEcCtD
Imiquimod—Erythema—Methotrexate—psoriasis	2.32e-05	0.00015	CcSEcCtD
Imiquimod—Malnutrition—Methotrexate—psoriasis	2.32e-05	0.00015	CcSEcCtD
Imiquimod—Hypersensitivity—Prednisolone—psoriasis	2.3e-05	0.000148	CcSEcCtD
Imiquimod—Dyspepsia—Betamethasone—psoriasis	2.29e-05	0.000148	CcSEcCtD
Imiquimod—Dyspepsia—Dexamethasone—psoriasis	2.29e-05	0.000148	CcSEcCtD
Imiquimod—CYP1A2—Metabolism—NDUFA5—psoriasis	2.29e-05	0.000594	CbGpPWpGaD
Imiquimod—Diarrhoea—Mycophenolate mofetil—psoriasis	2.29e-05	0.000148	CcSEcCtD
Imiquimod—Urticaria—Triamcinolone—psoriasis	2.28e-05	0.000147	CcSEcCtD
Imiquimod—Body temperature increased—Triamcinolone—psoriasis	2.27e-05	0.000146	CcSEcCtD
Imiquimod—Dizziness—Cyclosporine—psoriasis	2.27e-05	0.000146	CcSEcCtD
Imiquimod—Oedema—Prednisone—psoriasis	2.27e-05	0.000146	CcSEcCtD
Imiquimod—Decreased appetite—Dexamethasone—psoriasis	2.26e-05	0.000146	CcSEcCtD
Imiquimod—Decreased appetite—Betamethasone—psoriasis	2.26e-05	0.000146	CcSEcCtD
Imiquimod—Infection—Prednisone—psoriasis	2.25e-05	0.000145	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Dexamethasone—psoriasis	2.25e-05	0.000145	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Betamethasone—psoriasis	2.25e-05	0.000145	CcSEcCtD
Imiquimod—Back pain—Methotrexate—psoriasis	2.25e-05	0.000145	CcSEcCtD
Imiquimod—Hypersensitivity—Hydrocortisone—psoriasis	2.25e-05	0.000145	CcSEcCtD
Imiquimod—Fatigue—Dexamethasone—psoriasis	2.25e-05	0.000145	CcSEcCtD
Imiquimod—Fatigue—Betamethasone—psoriasis	2.25e-05	0.000145	CcSEcCtD
Imiquimod—Shock—Prednisone—psoriasis	2.23e-05	0.000144	CcSEcCtD
Imiquimod—Pain—Dexamethasone—psoriasis	2.23e-05	0.000144	CcSEcCtD
Imiquimod—Pain—Betamethasone—psoriasis	2.23e-05	0.000144	CcSEcCtD
Imiquimod—Nervous system disorder—Prednisone—psoriasis	2.22e-05	0.000143	CcSEcCtD
Imiquimod—Tachycardia—Prednisone—psoriasis	2.21e-05	0.000143	CcSEcCtD
Imiquimod—Dizziness—Mycophenolate mofetil—psoriasis	2.21e-05	0.000143	CcSEcCtD
Imiquimod—Skin disorder—Prednisone—psoriasis	2.2e-05	0.000142	CcSEcCtD
Imiquimod—Hyperhidrosis—Prednisone—psoriasis	2.19e-05	0.000141	CcSEcCtD
Imiquimod—Asthenia—Hydrocortisone—psoriasis	2.19e-05	0.000141	CcSEcCtD
Imiquimod—Vomiting—Cyclosporine—psoriasis	2.18e-05	0.000141	CcSEcCtD
Imiquimod—TLR7—Immune System—IL6—psoriasis	2.18e-05	0.000565	CbGpPWpGaD
Imiquimod—Rash—Cyclosporine—psoriasis	2.16e-05	0.000139	CcSEcCtD
Imiquimod—Anorexia—Prednisone—psoriasis	2.16e-05	0.000139	CcSEcCtD
Imiquimod—Dermatitis—Cyclosporine—psoriasis	2.16e-05	0.000139	CcSEcCtD
Imiquimod—Pruritus—Hydrocortisone—psoriasis	2.16e-05	0.000139	CcSEcCtD
Imiquimod—Ill-defined disorder—Methotrexate—psoriasis	2.16e-05	0.000139	CcSEcCtD
Imiquimod—Headache—Cyclosporine—psoriasis	2.15e-05	0.000139	CcSEcCtD
Imiquimod—Feeling abnormal—Dexamethasone—psoriasis	2.15e-05	0.000138	CcSEcCtD
Imiquimod—Feeling abnormal—Betamethasone—psoriasis	2.15e-05	0.000138	CcSEcCtD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.14e-05	0.000554	CbGpPWpGaD
Imiquimod—Gastrointestinal pain—Dexamethasone—psoriasis	2.13e-05	0.000137	CcSEcCtD
Imiquimod—Gastrointestinal pain—Betamethasone—psoriasis	2.13e-05	0.000137	CcSEcCtD
Imiquimod—Vomiting—Mycophenolate mofetil—psoriasis	2.13e-05	0.000137	CcSEcCtD
Imiquimod—Hypersensitivity—Triamcinolone—psoriasis	2.12e-05	0.000136	CcSEcCtD
Imiquimod—Rash—Mycophenolate mofetil—psoriasis	2.11e-05	0.000136	CcSEcCtD
Imiquimod—Dermatitis—Mycophenolate mofetil—psoriasis	2.11e-05	0.000136	CcSEcCtD
Imiquimod—Headache—Mycophenolate mofetil—psoriasis	2.1e-05	0.000135	CcSEcCtD
Imiquimod—Malaise—Methotrexate—psoriasis	2.09e-05	0.000135	CcSEcCtD
Imiquimod—Diarrhoea—Hydrocortisone—psoriasis	2.09e-05	0.000134	CcSEcCtD
Imiquimod—Urticaria—Betamethasone—psoriasis	2.07e-05	0.000133	CcSEcCtD
Imiquimod—Urticaria—Dexamethasone—psoriasis	2.07e-05	0.000133	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Prednisone—psoriasis	2.07e-05	0.000133	CcSEcCtD
Imiquimod—Dizziness—Prednisolone—psoriasis	2.06e-05	0.000133	CcSEcCtD
Imiquimod—Asthenia—Triamcinolone—psoriasis	2.06e-05	0.000133	CcSEcCtD
Imiquimod—Abdominal pain—Dexamethasone—psoriasis	2.06e-05	0.000133	CcSEcCtD
Imiquimod—Abdominal pain—Betamethasone—psoriasis	2.06e-05	0.000133	CcSEcCtD
Imiquimod—Body temperature increased—Dexamethasone—psoriasis	2.06e-05	0.000133	CcSEcCtD
Imiquimod—Body temperature increased—Betamethasone—psoriasis	2.06e-05	0.000133	CcSEcCtD
Imiquimod—Insomnia—Prednisone—psoriasis	2.05e-05	0.000132	CcSEcCtD
Imiquimod—Nausea—Cyclosporine—psoriasis	2.04e-05	0.000131	CcSEcCtD
Imiquimod—Paraesthesia—Prednisone—psoriasis	2.04e-05	0.000131	CcSEcCtD
Imiquimod—Pruritus—Triamcinolone—psoriasis	2.03e-05	0.000131	CcSEcCtD
Imiquimod—Cough—Methotrexate—psoriasis	2.03e-05	0.000131	CcSEcCtD
Imiquimod—Dizziness—Hydrocortisone—psoriasis	2.02e-05	0.00013	CcSEcCtD
Imiquimod—Convulsion—Methotrexate—psoriasis	2.01e-05	0.00013	CcSEcCtD
Imiquimod—Dyspepsia—Prednisone—psoriasis	2e-05	0.000129	CcSEcCtD
Imiquimod—Nausea—Mycophenolate mofetil—psoriasis	1.99e-05	0.000128	CcSEcCtD
Imiquimod—Myalgia—Methotrexate—psoriasis	1.98e-05	0.000127	CcSEcCtD
Imiquimod—Chest pain—Methotrexate—psoriasis	1.98e-05	0.000127	CcSEcCtD
Imiquimod—Arthralgia—Methotrexate—psoriasis	1.98e-05	0.000127	CcSEcCtD
Imiquimod—Decreased appetite—Prednisone—psoriasis	1.97e-05	0.000127	CcSEcCtD
Imiquimod—Rash—Prednisolone—psoriasis	1.97e-05	0.000127	CcSEcCtD
Imiquimod—Dermatitis—Prednisolone—psoriasis	1.97e-05	0.000127	CcSEcCtD
Imiquimod—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	1.96e-05	0.000127	CcSEcCtD
Imiquimod—Fatigue—Prednisone—psoriasis	1.96e-05	0.000126	CcSEcCtD
Imiquimod—Headache—Prednisolone—psoriasis	1.96e-05	0.000126	CcSEcCtD
Imiquimod—Discomfort—Methotrexate—psoriasis	1.95e-05	0.000126	CcSEcCtD
Imiquimod—CYP1A2—Metabolism—CYP2S1—psoriasis	1.95e-05	0.000505	CbGpPWpGaD
Imiquimod—Vomiting—Hydrocortisone—psoriasis	1.94e-05	0.000125	CcSEcCtD
Imiquimod—Rash—Hydrocortisone—psoriasis	1.92e-05	0.000124	CcSEcCtD
Imiquimod—Dermatitis—Hydrocortisone—psoriasis	1.92e-05	0.000124	CcSEcCtD
Imiquimod—Headache—Hydrocortisone—psoriasis	1.91e-05	0.000123	CcSEcCtD
Imiquimod—Dizziness—Triamcinolone—psoriasis	1.9e-05	0.000122	CcSEcCtD
Imiquimod—Infection—Methotrexate—psoriasis	1.88e-05	0.000121	CcSEcCtD
Imiquimod—Feeling abnormal—Prednisone—psoriasis	1.87e-05	0.00012	CcSEcCtD
Imiquimod—Asthenia—Dexamethasone—psoriasis	1.87e-05	0.00012	CcSEcCtD
Imiquimod—Asthenia—Betamethasone—psoriasis	1.87e-05	0.00012	CcSEcCtD
Imiquimod—Nervous system disorder—Methotrexate—psoriasis	1.86e-05	0.00012	CcSEcCtD
Imiquimod—Gastrointestinal pain—Prednisone—psoriasis	1.86e-05	0.00012	CcSEcCtD
Imiquimod—Nausea—Prednisolone—psoriasis	1.85e-05	0.00012	CcSEcCtD
Imiquimod—Pruritus—Dexamethasone—psoriasis	1.84e-05	0.000119	CcSEcCtD
Imiquimod—Pruritus—Betamethasone—psoriasis	1.84e-05	0.000119	CcSEcCtD
Imiquimod—Skin disorder—Methotrexate—psoriasis	1.84e-05	0.000119	CcSEcCtD
Imiquimod—Hyperhidrosis—Methotrexate—psoriasis	1.83e-05	0.000118	CcSEcCtD
Imiquimod—Vomiting—Triamcinolone—psoriasis	1.83e-05	0.000118	CcSEcCtD
Imiquimod—Nausea—Hydrocortisone—psoriasis	1.81e-05	0.000117	CcSEcCtD
Imiquimod—Rash—Triamcinolone—psoriasis	1.81e-05	0.000117	CcSEcCtD
Imiquimod—Dermatitis—Triamcinolone—psoriasis	1.81e-05	0.000117	CcSEcCtD
Imiquimod—Anorexia—Methotrexate—psoriasis	1.81e-05	0.000116	CcSEcCtD
Imiquimod—Urticaria—Prednisone—psoriasis	1.8e-05	0.000116	CcSEcCtD
Imiquimod—Headache—Triamcinolone—psoriasis	1.8e-05	0.000116	CcSEcCtD
Imiquimod—Abdominal pain—Prednisone—psoriasis	1.79e-05	0.000116	CcSEcCtD
Imiquimod—Body temperature increased—Prednisone—psoriasis	1.79e-05	0.000116	CcSEcCtD
Imiquimod—Diarrhoea—Dexamethasone—psoriasis	1.78e-05	0.000115	CcSEcCtD
Imiquimod—Diarrhoea—Betamethasone—psoriasis	1.78e-05	0.000115	CcSEcCtD
Imiquimod—CYP3A4—Metabolism—NDUFA5—psoriasis	1.77e-05	0.000458	CbGpPWpGaD
Imiquimod—Musculoskeletal discomfort—Methotrexate—psoriasis	1.73e-05	0.000111	CcSEcCtD
Imiquimod—Dizziness—Dexamethasone—psoriasis	1.72e-05	0.000111	CcSEcCtD
Imiquimod—Dizziness—Betamethasone—psoriasis	1.72e-05	0.000111	CcSEcCtD
Imiquimod—Insomnia—Methotrexate—psoriasis	1.71e-05	0.000111	CcSEcCtD
Imiquimod—Nausea—Triamcinolone—psoriasis	1.71e-05	0.00011	CcSEcCtD
Imiquimod—Paraesthesia—Methotrexate—psoriasis	1.7e-05	0.00011	CcSEcCtD
Imiquimod—Dyspnoea—Methotrexate—psoriasis	1.69e-05	0.000109	CcSEcCtD
Imiquimod—Somnolence—Methotrexate—psoriasis	1.69e-05	0.000109	CcSEcCtD
Imiquimod—Hypersensitivity—Prednisone—psoriasis	1.67e-05	0.000108	CcSEcCtD
Imiquimod—Dyspepsia—Methotrexate—psoriasis	1.67e-05	0.000108	CcSEcCtD
Imiquimod—Vomiting—Dexamethasone—psoriasis	1.66e-05	0.000107	CcSEcCtD
Imiquimod—Vomiting—Betamethasone—psoriasis	1.66e-05	0.000107	CcSEcCtD
Imiquimod—Decreased appetite—Methotrexate—psoriasis	1.65e-05	0.000106	CcSEcCtD
Imiquimod—Rash—Betamethasone—psoriasis	1.64e-05	0.000106	CcSEcCtD
Imiquimod—Rash—Dexamethasone—psoriasis	1.64e-05	0.000106	CcSEcCtD
Imiquimod—Dermatitis—Dexamethasone—psoriasis	1.64e-05	0.000106	CcSEcCtD
Imiquimod—Dermatitis—Betamethasone—psoriasis	1.64e-05	0.000106	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Methotrexate—psoriasis	1.64e-05	0.000105	CcSEcCtD
Imiquimod—Fatigue—Methotrexate—psoriasis	1.63e-05	0.000105	CcSEcCtD
Imiquimod—Headache—Dexamethasone—psoriasis	1.63e-05	0.000105	CcSEcCtD
Imiquimod—Headache—Betamethasone—psoriasis	1.63e-05	0.000105	CcSEcCtD
Imiquimod—Asthenia—Prednisone—psoriasis	1.63e-05	0.000105	CcSEcCtD
Imiquimod—Pain—Methotrexate—psoriasis	1.62e-05	0.000104	CcSEcCtD
Imiquimod—Pruritus—Prednisone—psoriasis	1.61e-05	0.000103	CcSEcCtD
Imiquimod—Feeling abnormal—Methotrexate—psoriasis	1.56e-05	0.000101	CcSEcCtD
Imiquimod—Diarrhoea—Prednisone—psoriasis	1.55e-05	0.0001	CcSEcCtD
Imiquimod—Gastrointestinal pain—Methotrexate—psoriasis	1.55e-05	9.99e-05	CcSEcCtD
Imiquimod—Nausea—Betamethasone—psoriasis	1.55e-05	9.97e-05	CcSEcCtD
Imiquimod—Nausea—Dexamethasone—psoriasis	1.55e-05	9.97e-05	CcSEcCtD
Imiquimod—Urticaria—Methotrexate—psoriasis	1.51e-05	9.71e-05	CcSEcCtD
Imiquimod—CYP3A4—Metabolism—CYP2S1—psoriasis	1.5e-05	0.00039	CbGpPWpGaD
Imiquimod—Dizziness—Prednisone—psoriasis	1.5e-05	9.67e-05	CcSEcCtD
Imiquimod—Abdominal pain—Methotrexate—psoriasis	1.5e-05	9.66e-05	CcSEcCtD
Imiquimod—Body temperature increased—Methotrexate—psoriasis	1.5e-05	9.66e-05	CcSEcCtD
Imiquimod—Vomiting—Prednisone—psoriasis	1.44e-05	9.3e-05	CcSEcCtD
Imiquimod—Rash—Prednisone—psoriasis	1.43e-05	9.22e-05	CcSEcCtD
Imiquimod—Dermatitis—Prednisone—psoriasis	1.43e-05	9.21e-05	CcSEcCtD
Imiquimod—Headache—Prednisone—psoriasis	1.42e-05	9.16e-05	CcSEcCtD
Imiquimod—Hypersensitivity—Methotrexate—psoriasis	1.4e-05	9e-05	CcSEcCtD
Imiquimod—Asthenia—Methotrexate—psoriasis	1.36e-05	8.77e-05	CcSEcCtD
Imiquimod—Nausea—Prednisone—psoriasis	1.35e-05	8.68e-05	CcSEcCtD
Imiquimod—Pruritus—Methotrexate—psoriasis	1.34e-05	8.64e-05	CcSEcCtD
Imiquimod—Diarrhoea—Methotrexate—psoriasis	1.3e-05	8.36e-05	CcSEcCtD
Imiquimod—Dizziness—Methotrexate—psoriasis	1.25e-05	8.08e-05	CcSEcCtD
Imiquimod—Vomiting—Methotrexate—psoriasis	1.21e-05	7.77e-05	CcSEcCtD
Imiquimod—Rash—Methotrexate—psoriasis	1.2e-05	7.7e-05	CcSEcCtD
Imiquimod—Dermatitis—Methotrexate—psoriasis	1.19e-05	7.7e-05	CcSEcCtD
Imiquimod—Headache—Methotrexate—psoriasis	1.19e-05	7.65e-05	CcSEcCtD
Imiquimod—Nausea—Methotrexate—psoriasis	1.13e-05	7.26e-05	CcSEcCtD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.02e-05	0.000265	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CARM1—psoriasis	9.51e-06	0.000247	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.89e-06	0.00023	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CARM1—psoriasis	7.34e-06	0.00019	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CAT—psoriasis	5.85e-06	0.000152	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—APOE—psoriasis	4.55e-06	0.000118	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CAT—psoriasis	4.51e-06	0.000117	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PPARG—psoriasis	3.96e-06	0.000103	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—APOE—psoriasis	3.51e-06	9.09e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PPARG—psoriasis	3.06e-06	7.92e-05	CbGpPWpGaD
